FairWarning
By Patrick Corcoran on December 28, 2010
A new British anti-bribery law taking effect in April is spurring multinational companies to strengthen their compliance programs.
According to The Wall Street Journal, British officials may use the law — modeled after the U.S. Foreign Corrupt Practices Act but considered more stringent — to target pharmaceutical companies.